Report of Foreign Issuer (6-k)
November 18 2019 - 4:38PM
Edgar (US Regulatory)
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549 FORM 6-K
REPORT
OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER
THE SECURITIES EXCHANGE ACT OF 1934
For the month of November
2019.
Commission File
Number: 000-53805
Intellipharmaceutics International
Inc.
(Translation of
registrant's name into English)
30
WORCESTER ROAD TORONTO, ONTARIO M9W 5X2
(Address of
principal executive office)
Indicate by check
mark whether the registrant files or will file annual reports under
cover of Form 20-F or Form 40-F. Form 20-F[X] Form 40-F[
]
Indicate by check
mark if the registrant is submitting the Form 6-K in paper as
permitted by Regulation S-T Rule 101(b)(1):___
Note: Regulation S-T Rule 101(b)(1) only
permits the submission in paper of a Form 6-K if submitted solely
to provide an attached annual report to security
holders.
Indicate by check
mark if the registrant is submitting the Form 6-K in paper as
permitted by Regulation S-T Rule
101(b)(7):___
Note: Regulation S-T Rule 101(b)(7) only
permits the submission in paper of a Form 6-K if submitted to
furnish a report or other document that the registrant foreign
private issuer must furnish and make public under the laws of the
jurisdiction in which the registrant is incorporated, domiciled or
legally organized (the registrant’s “home
country”), or under the rules of the home country exchange on
which the registrant’s securities are traded, as long as the
report or other document is not a press release, is not required to
be and has not been distributed to the registrant’s security
holders, and, if discussing a material event, has already been the
subject of a Form 6-K submission or other Commission filing on
EDGAR.
This
Report of Foreign Private Issuer on Form 6-K and the attached
Exhibit 99.1 shall be incorporated by reference into the
Company’s effective Registration Statements on Form F-3, as
amended and supplemented (Registration Statement Nos. 333-172796
and 333-218297), filed with the Securities and Exchange Commission,
from the date on which this Report is filed, to the extent not
superseded by documents or reports subsequently filed or furnished
by Intellipharmaceutics International Inc. under the Securities Act
of 1933 or the Securities Exchange Act of 1934.
EXHIBIT LIST
The
following exhibit is attached to this report on Form
6-K:
Exhibit
No.
|
Description
|
99.1
|
Press release
dated November 18, 2019 - Intellipharmaceutics Closes US$250,000
Convertible Debenture Financing with Drs. Isa and Amina
Odidi.
|
99.2
|
Early Warning
Report November 18, 2019.
|
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf
by the undersigned, thereunto duly authorized.
|
Intellipharmaceutics International Inc.
Registrant
|
Date:
November 18, 2019
|
By:
|
/s/ Greg
Powell
|
|
|
Greg
Powell
Chief
Financial Officer
|
IntelliPharmaCeutics (CE) (USOTC:IPCIF)
Historical Stock Chart
From Jun 2024 to Jul 2024
IntelliPharmaCeutics (CE) (USOTC:IPCIF)
Historical Stock Chart
From Jul 2023 to Jul 2024